• Doximity recently came under pressure as part of a broader sell-off in technology and healthcare software stocks, driven by investor worries about potential disruption from artificial intelligence.
• Despite this pressure, analyst expectations still point to higher quarterly revenue and growth in larger customers, even as projected earnings per share soften slightly compared to a year earlier.
• Given the recent 10.5% seven-day share price decline, we'll examine how AI-disruption concerns shape Doximity's investment narrative and growth outlook.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Doximity's Investment Narrative?

To own Doximity, you really have to believe that its niche at the intersection of physicians and healthcare marketers is durable, even as AI reshapes software across the sector. The core near term catalysts still look tied to execution on its US$640–646 million fiscal 2026 revenue guidance, continued expansion in larger accounts and the support from an active US$500 million buyback that has already retired millions of shares. The recent AI-driven sell-off and 10.5% seven-day share price drop mostly affects sentiment rather than these operational drivers, especially with analysts still expecting revenue and large-customer growth ahead of the upcoming earnings release. Where it does matter is on the risk side: AI disruption worries now sit alongside existing concerns about rich valuation, slowing forecast growth and governance questions around high CEO pay.

However, investors should be aware that AI-related disruption fears may not fade quickly. Despite retreating, Doximity's shares might still be trading 33% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Seven Simply Wall St Community fair value estimates span roughly US$41 to US$83 per share, showing how far apart individual views can be. Against that spread, the recent AI-driven sell-off and questions about growth durability give you strong reasons to compare several of these perspectives before deciding how Doximity’s risk profile fits your portfolio.

Explore 7 other fair value estimates on Doximity - why the stock might be worth over 2x more than the current price!

Build Your Own Doximity Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Doximity research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find companies with promising cash flow potential yet trading below their fair value.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.